Payment overview · 2025
General Payments
$415.17
12 reported records · 7 companies
Healthcare provider profile · identity verified
John James Burnett, DO
Allopathic & Osteopathic Physicians|Family Medicine · EVANS MILLS, NY · NPI 1366892846
Verified facts
What the public records show
CMS Open Payments records show John James Burnett, DO received $415.17 in general payments during 2025 across 12 reported records.
Madrigal Pharmaceuticals accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $167.22 | 40.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.01 | 18.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.84 | 16.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.26 | 9.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.52 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.13 | 4.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.19 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.17 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $167.22 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $76.01 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $69.84 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 102 |
| Omeprazole | Omeprazole | 237 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 44 |
| Gabapentin | Gabapentin | 206 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 55 |
| Lisinopril | Lisinopril | 191 | 60 |
| Metformin Hcl | Metformin Hcl | 176 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 42 |
| Losartan Potassium | Losartan Potassium | 123 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 37 |
| Simvastatin | Simvastatin | 119 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 26 |
| Trazodone Hcl | Trazodone Hcl | 105 | 31 |
| Famotidine | Famotidine | 96 | 21 |
| Jardiance | Empagliflozin | 95 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 93 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 27 |
| Furosemide | Furosemide | 82 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 24 |
| Eliquis | Apixaban | 79 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 27 |
| Ozempic | Semaglutide | 71 | 16 |
| Sertraline Hcl | Sertraline Hcl | 70 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 11 |
| Carvedilol | Carvedilol | 63 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 17 |
| Meloxicam | Meloxicam | 60 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 11 |
| Montelukast Sodium | Montelukast Sodium | 53 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 12 |
| Glipizide | Glipizide | 52 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 11 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Baclofen | Baclofen | 45 | 11 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 11 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Fluconazole | Fluconazole | 14 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.17 · 12 records | Madrigal Pharmaceuticals | AIRSUPRA, AREXVY, JARDIANCE, MOUNJARO, REZDIFFRA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error